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Abstract
Background: Phospholipase A2 (PLA2) is a major component of the Daboia siamensis venom, which is able to
hydrolyse the membrane of various cells. For this reason, the activity of PLA2 was investigated regarding its
pharmaceutical properties. This study was conducted to explore the pharmacological properties of a PLA2 from
Daboia siamensis (dssPLA2) venom on human skin melanoma cell line (SK-MEL-28).
Methods: dssPLA2 was isolated by ion exchange and gel filtration columns. Various concentrations of dssPLA2 were
investigated for cytotoxic activity and inhibition of migration on SK-MEL-28 cells. Cell death analysis, mRNA
expression levels of Notch I-III and BRAF V600E genes were also determined.
Results: dssPLA2 exhibited cytotoxicity on SK-MEL-28 for 24 and 72 h as compared with untreated cells. However, it
had no toxic effects on CCD-1064sk cells under the same conditions. dssPLA2 (0.25 and 0.5 μg/mL) induced 17.16
and 30.60 % of apoptosis, while activated 6.53 and 7.05 % of necrotic cells. dssPLA2 at 0.25, 0.5, 1 and 2 μg/mL
could inhibit migration on SK-MEL-28 cells for 24 h by 31.06, 41.66, 50 and 68.75 %, respectively. The action of
dssPLA2 significantly reduced the levels of Notch I and BRAF V600E genes expression on SK-MEL-28 cells compared
with untreated cells at 72 h.
Conclusions: This study indicates that dssPLA2 had potential effects of apoptosis, necrosis, cytotoxicity and
inhibition of migration on SK-MEL-28 cells. dssPLA2 could possibly be a selective agent that targets cancer cells
without affecting normal cells.
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Background
Skin cancer, especially melanoma, is a medical problem
with increasing incidence that is generally asymptomatic
[1]. The risk factors for melanoma depends on several
elements, including sun exposure, number of moles on
the skin, skin type and family history [2]. Most malig-
nant melanomas have mutation of the BRAF gene lead-
ing to constitutive activation of downstream signaling in
the mitogen-activated protein (MAP) kinase pathway.
The activating mutation consists of the substitution of
glutamic acid for valine at amino acid 600 (V600E).
Detection of BRAF V600E mutation gene bears relation-
ship to survival and proliferation of cancer cells [3].
The surgical treatment in early stages of the disease is ef-
fective whereas treatment at late stages present low survival
rates. Chemotherapy is a therapeutic option. However, its
efficacy is limited due to chemoresistance and toxicity. Re-
cently, new agents obtained from natural substances have
been studied for their specificity against cancer cells and
mild effects towards normal cells. For example, effects of
rottlerin, involving the dual inhibition of ERK and NF-κB
and downregulation of cyclin D1, led to antiproliferation
on SK-MEL-28 cells [4]. Gossypol, a cottonseed extract,
has shown effective therapeutic action against BRAF
V600E melanoma with resistance to BRAF inhibitors [5].
Three xanthones induced an inhibitory effect on SK-MEL-
* Correspondence: sthaithumnas@yahoo.com
1Research and Development, Queen Saovabha Memorial Institute, Thai Red
Cross Society, Bangkok 10330, Thailand
Full list of author information is available at the end of the article
© 2016 Khunsap et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Khunsap et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:7 
DOI 10.1186/s40409-016-0061-z
28 cell by modulating the BRAF V600E mutation and the
other molecular targets in the apoptotic pathways [6].
Many small molecules have been studied in experimen-
tal and clinical trials. For example, vemurafenib, dabra-
fenib and trametinib, and serine/threonine kinase
inhibitors have been tested in experiments and clinical
trials as inhibitors for BRAF V600E mutation gene and
MEK1/2 of MAPK pathway, respectively [7]. However,
melanoma cell lines treated with these BRAF inhibitors
have shown to rebound activation of phosphorylation of
ERK (pERK) and escape from BRAF inhibition [8]. The
progressed tumor returned within 6 to 8 months after
therapy of these agents [9].
The disorder of Notch signaling pathways was associated
with tumor genesis of tissues from various origins and also
skin melanoma [10, 11]. Notch and their ligands are abun-
dantly expressed in the epidermis, either as an oncogene or
as a tumor suppressor on melanoma and non-melanoma
[12]. The importance of Notch signaling pathway in deter-
mining the outcome of treatment has been reported [13].
Both BRAF V600E mutation and Notch signaling pathway
should be studied as bioactive agents against melanoma.
PLA2 is one of the major components of snake venom
for the digestion of prey [14]. Multifunctional effects of
this enzyme have been documented [15, 16]. It directly
catalyzes the hydrolysis of cellular phospholipids that gen-
erate lysophospholipids and free fatty acids that, in turn,
cause membrane damage [17, 18]. Lysophospholipids are
important in cell signaling, phospholipid remodeling and
membrane perturbation [19]. Some evidence indicated
that PLA2 hydrolyzed cellular membrane of various can-
cer cells [20]. In a study of membrane-interacted mode
and catalytic activity, a PLA2 of Naja naja atra was able
to catalyze outer leaflet and inner leaflet of plasma
membrane-mimicking vesicles [21]. The venom from
Macrovipera lebetina transmediterranea has shown to
have antitumor effects mediated by α5β1 and αv-
containing integrins [22]. Therefore, PLA2 properties indi-
cated high activity against skin melanoma cancers.
Our previous study demonstrated the action of a PLA2
from Daboia siamensis (drsPLA2) against cancer cells [23].
In order to better understand the pharmacological action of
dssPLA2 from Daboia siamensis against skin melanoma
cells, the current work is focused on the process of migra-
tion inhibition, cytotoxicity and gene expression. Apoptosis
analysis was also determined on skin melanoma cells. An
investigation of molecular targets was performed to identify
BRAF V600E mutation gene and Notch signaling receptors;
N1, N2 and N3 genes.
Methods
Cell cultures
Human skin melanoma SK-MEL-28 (ATCC® HTB-
72™) cells and skin fibroblast CCD-1064Sk (ATCC®
CRL-2076™) cells were purchased from the American
Type Culture Collection (ATCC, USA). SK-MEL-28
and CCD-1064sk cells were cultured in MEM and
Iscove’s media supplemented with 10 % fetal bovine
serum (FBS), 1 mM glutamine, 100 U/mL strepto-
mycin and 100 U/mL penicillin. Cells were incubated
at 37 °C with 5 % CO2. The media, FBS, strepto-
mycin, penicillin and MTT 3-(4,-5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) were
purchased from Invitrogen, USA.
Venom separation by FPLC and SDS-PAGE
Crude venom from Daboia siamensis in lyophilized
form was dissolved with 0.02 M phosphate buffer,
pH 6.0. The venom solution (approximately 40 mg/
mL) was applied to ion exchange chromatography on
HiTrap™ CM FF column. The column was pre-
equilibrated with 0.02 M phosphate buffer, pH 6.0. The
proteins were eluted with 0–1 M NaCl linear gradient
in 0.02 M phosphate buffer, pH 6.0, at a flow rate
0.5 mL/min. The proteins were collected and measured
at absorbance 280 nm under an AKTA pure Fast Pro-
tein Liquid Chromatography system (FPLC, GE
Healthcare; Sweden). Four peaks were observed and
determined for phospholipase A2 activity. Peak 2,
showed PLA2 enzyme activity (gray shaded area in
Fig. 1a), was then further purified by size exclusion
chromatography in a pre-equilibrated Superdex 75 10/
100 GL column. Elution was carried out with 10 mM
PBS, pH 7.3, at room temperature. The flow rate was
adjusted to 0.5 mL/min., and 1 mL fraction was col-
lected in each tube. The proteins were detected by ab-
sorbance at 280 nm under a Unicorn 6.3 Software.
Four peaks were collected and tested for PLA2 activity.
Peak 2 showed a PLA2 activity (gray shaded area in
Fig. 1b) indicating a low molecular weight protein
(below 17 kDa) on SDS-PAGE (Fig. 1c).
Each PLA2 fraction was analyzed on SDS containing
polyacrylamide slab gels according to a modified method
of Laemmli. The 12.5 % acrylamide in 3.0 M Tris–HCl,
pH 8.8, was prepared in the presence of 0.1 % SDS. The
venom samples (10 μg of protein) were mixed with a
sample buffer and loaded onto a 12.5 % gel under non-
reducing conditions. Electrophoresis was carried out at
room temperature using 30 mA in the separating
process. The precision plus protein standards were used
as molecular weight markers. The electrophoresis was
stopped when the marker dye reached the bottom of the
gel. The electrophoresis gel was stained for 1 h with the
Coomassie Brilliant Blue R-250 (0.2 % in methanol/
water/acetic acid, 46.5: 46.5:7) and the excess stain was
then removed by de-staining (methanol/acetic acid, 25:
12.5) with several changes of de-staining solution until
the background was clear.
Khunsap et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:7 Page 2 of 8
Determination of molecular mass
The gel containing dssPLA2 was purified by a conven-
tional method using a clean scalpel to cut off a strip of
15 % Tris-glycine SDS-PAGE. The sample was analyzed
by mass spectrometry. Briefly, the excised gel was shred-
ded and washed three times with 200 μL of 25 mM
NH4HCO3/50 % acetonitrile (ACN). The gels were dehy-
drated with 200 μL of 100 % CAN, then rehydrated by
12.5 μg/mL of sequencing grade trypsin (Promega, USA)
and incubated at 37 °C for 16 h. The supernatant was
transferred to a new tube and added 100 μL of 50 %
ACN/0.5 % formic acid. The mixture was finally dried
by speedvac and suspended in 10 μL of 50 % ACN/0.1 %
formic acid. The peptides were analyzed by MS/MS
using microTOF-Q II™ ESI-Qq-TOF mass spectrometer
(Bruker, Germany) equipped with an online nanoESI
source. MASCOT is a software search engine that iden-
tifies proteins based on peptide sequence databases.
Mass tolerance of parent and fragmented ions were
1.0 Da and 0.6 Da, respectively. MS/MS ions score ≥38
were considered significant hits.
Phospholipase A2 activity
Phospholipase A2 activity was performed by Holzer and
Mackessy method [24]. The sample (50 μL) was mixed
with 3 mM 4-nitro-3-(octanoyloxy) benzoic acid 1:1
ratio (v/v) and incubated at 37 °C for 20 min. Triton X-
100 (2.5 %) was added to the reaction mix and the ab-
sorbance was measured at 425 nm by ELISA reader. A
standard curve of absorbance as a function of chromo-
phore (3-hydroxy-4-nitrobenzoic acid) concentration
showed that a change in absorbance of 0.10 AU at
425 nm was equivalent to 25.8 nmoles of chromophore
release. The chromophore has an extinction coefficient
of 5039 in this system. This sample was used as PLA2
fraction in the study of migration inhibition, apoptosis,
cytotoxic activity, Notch signaling and BRAF V600E mu-
tation genes expression on SK-MEL-28 cell line.
Cytotoxic analysis
The MTT assay was chosen for determining the cyto-
toxic effect of venoms [25, 26]. Briefly, cells were seeded
into 96-well plates (NUNC, Denmark) at concentration
of 5 × 104 cells/mL and incubated at 37 °C with 5 % CO2
for 24 h. The cells were treated with various concentra-
tions of venom (0.25, 0.5, 1, 2 and 4 μg/mL) for 24 and
72 h. Cell viability was determined by adding 20 μL of
MTT (2.5 mg/mL) for 3 h. An absolute DMSO (150 μL)
was added to dissolve the formazan crystal. In the exper-
iments, absorbance was measured at 540 nm and un-
treated cells were used for setting 100 % viability.
Apoptosis analysis
SK-MEL-28 cells were seeded into 6-well plates and incu-
bated at 37 °C with 5 % CO2 for 24 h. The dssPLA2 (0.25
and 0.5 μg/mL) were added then incubation continued for
the next 24 houra. Apoptotic and necrotic cells were de-
tected with AnnexinV apoptosis detection kit (USA),
which is based on the observation after initial apoptosis.
Cells translocate the membrane phosphatidylserine (PS)
from the inner face of the plasma membrane to the cell
surface. PS can be detected by staining with a fluorescent
isothiocyanate (FITC) conjugate of AnnexinV while propi-
dium iodide (PI) binds to the cellular DNA in necrotic
cells. The staining process was performed following the
manufacturer’s instructions. Cells were acquired and ana-
lyzed by FACSCalibur flow cytometry and CellQuest Pro
software (Becton Dickinson, San Jose, USA).
Fig. 1 A dssPLA2 was isolated from Daboia siamensis venom. (a) Ion exchange chromatography of Daboia siamensis venom on HiTrap™ CM FF column.
Protein was eluted with linear gradient 0–1 M NaCl. The peak with gray-shaded area was PLA2 activity. (b) Peak 2 from the first step was applied on
Superdex™ 75 10/300 GL column. Elution was carried out with 10 mM PBS, pH 7.3. (c) SDS-PAGE analysis of venom and theirs fractions. Lane 1: protein
markers, lane 2: crude venom, lane 3: fraction no.2 from ion exchange chromatography, and lane 4: fraction no. 2 from gel filtration chromatography
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Inhibition of cell migration
Wound healing assay was performed for inhibition of cell
migration [23]. SK-MEL-28 cells were seeded into 24-well
plates (NUNC, Denmark) at 5 × 105 cells/mL concentra-
tion and incubated at 37 °C with 5 % CO2 for 24 h. After
24 h, the cells were scratched and washed twice with
medium without fetal bovine serum. The cells were
treated with various concentrations of dssPLA2 and doxo-
rubicin; an anticancer drug (2, 1, 0.5, 0.25 and 0 μg/mL)
for 24 h. Inhibition of migration was determined by meas-
uring the distance of the edge of scratching. The equation
of migration inhibition was 100 – [((Z-Tn)/Z) × 100]. Z is
the negative distance at time 0. Tn is the experiment dis-
tance at time 24 h.
Real time-reverse transcription-PCR (qRT-PCR)
qRT-PCR was performed by following manufacturers’ rec-
ommendations (RBC Sciences). Total RNA was extracted
from the SK-MEL-28 cells that were treated at 0.25 μg/mL
of dssPLA2 for 24 and 72 h. Untreated of SK-MEL-28 cells
were used as a negative control. One microgram of total
RNA was employed to generate cDNA using random hex-
amer primers. One microliter of 1:10 cDNA dilution was
applied to PCR reactions. Sequences of specific primers
were Notch1 forward: 5’-CAGCCTGCACAACCAGA-
CAGA-3’; reverse: 5’-TGAGTTGATGAGGTCCTCCAG-
3’; Notch2 forward: 5’-AAAAATGGGGCCAACCGAGAC-
3’; reverse: 5’-TCATCCAGAAGGCGCACA A-3’; Notch3
forward: 5’-AGATTCTCATCCGAAACCGCTCTA-3’; re-
verse: 5’-GGGGTCTCCTCCTTGC TATCCTG-3’; BRAF
V600E forward: 5’-AGGTGATTTTGGTCTAGCTACA
GA-3’; reverse: 5’-TAGTAACTCAGCAGCATCTCAGGG
C-3’; β-actin forward: 5’-ACCAACTGGGACGACATG GA
CAA-3’; reverse: 5’-GTGGTGGTGAAGCTGTAGCC-3’.
qRT-PCR was performed based on SYBR Green (RBC
Biosciences) to quantify the relative expression of BRAF
V600E mutation gene and Notch signaling receptors: N1,
N2, N3 genes. The mRNA level of the β-actin gene was de-
tected in each cDNA sample to normalize the expression
level of gene of interest (GOI). The ratio of GOI and β-
actin was compared among samples. The fold change of
GOI expression was acquired by setting the values from the
untreated cells to one. Calculation of expression level of
each gene that was normalized to the expression level of β-
actin by Delta Delta Ct equation: ΔΔCt =ΔCt (Target gene
treated – Reference gene treated) – ΔCt (Target gene con-
trol – Reference gene control). The mRNA expression gene
was calculated by 2 -(ΔΔCT). CT was a threshold cycle.
Statistical analysis
The statistical significance of the results was analyzed
using t-test (Primer of Biostatistics version 3.02). Differ-
ences between the mean values of results were consid-
ered statistical significant at p < 0.05.
Results
Purification of phospholipase A2
In the process of purification, Peak 2 from the second
step showed the highest PLA2 activity that increased
11.67 folds in the final step. The percent yield of
dssPLA2 was 27.0 % of crude venom protein. The size of
dssPLA2 was confirmed, 16.4 kDa, by using mass spec-
trometry. The summary of the purified method was dis-
played in Fig. 1. The purified protein was determined for
biological activities.
Cytotoxic analysis
SK-MEL-28 and CCD-1064sk cells were treated with
dssPLA2 at concentrations from 0 to 4 μg/mL for 24
and 72 h of incubation. dssPLA2 effects included dose-
and time-dependent cytotoxicity on SK-MEL-28 cells.
Viability of cells at 0.25, 0.5, 1, 2 and 4 μg/mL were,
respectively, 82.26 % ± 6.73, 72.38 % ± 7.66, 49.19 %
± 5.09, 32.52 % ± 3.3 and 17.82 % ± 4.17 for 24 h
whereas were 69.15 % ± 5.38, 32.65 % ± 3.42, 15.95 %
± 2.76, 10.23 % ± 3.35 and 5.3 % ± 1.21 for 72 h when
compared with untreated cells. Viability of SK-MEL-
28 cells at 72-h incubation was decreased approxi-
mately three fold at 1, 2 and 4 μg/mL and 1- and 2-
fold at 0.25 and 0.5 μg/mL dssPLA2 concentration
when compared with 24 h-incubation. However,
dssPLA2 was not toxic to CCD-1064sk cells at the
same conditions (Fig. 2).
Apoptosis analysis
dssPLA2 at 0.25 and 0.5 μg/mL induced, respectively,
17.16 and 30.60 % apoptosis in SK-MEL-28 cells. How-
ever, dssPLA2 also activated necrotic cells at 0.25
(6.53 %) and 0.5 μg/mL (7.05 %), while untreated SK-
MEL-28 cells showed signs of necrosis in 1.92 % of the
cells (Fig. 3). The results suggest that necrotic cells in-
creased when incubation time and concentration of
dssPLA2 augmented.
Inhibition of cell migration
Wound healing assay was a simple tool to detect inhib-
ition of SK-MEL-28 cells migration. The dssPLA2 inhib-
ited migration on SK-MEL-28 cells by 31.06 % at
0.25 μg/mL, 41.66 % at 0.5 μg/mL, 50 % at 1 μg/mL and
68.75 % at 2 μg/mL after 24 h of incubation. However,
more than 2 μg/mL of dssPLA2 did not increase inhib-
ition of migration. Moreover, doxorubicin, an antineo-
plastic drug, inhibited less than 50 % of migration at
concentrations up to 2 μg/mL (Fig. 4).
Notch signaling and BRAF V600E mutation genes analysis
Effects of dssPLA2 to Notch signaling pathway and BRAF
V600E mutation on SK-MEL-28 cells used real-time PCR
as a tool for gene expression analysis. SK-MEL-28 cells
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were treated with 0.25 μg/mL dssPLA2 after 24 and 72 h
of incubation. There was no significant change in mRNA
expression level of genes on SK-MEL-28 cells between
treated and untreated cells for 24 h. N1 and BRAF V600E
mutation genes showed significant decrease of mRNA ex-
pression level on SK-MEL-28 cells between treated and
untreated cells for 72 h (Fig. 5). The dssPLA2 did not sig-
nificantly affect N2 and N3 genes.
Discussion
Snake venom PLA2 are low molecular weight enzymes that
have different isoforms depending on their geographical
source and species of snakes [27]. In the present study, the
action of dssPLA2 damaged SK-MEL-28 cells by causing
cytotoxicity, apoptosis and inhibition of cell migration at
24 h and gene damage after 72 h of incubation. The
dssPLA2 showed no toxicity towards normal skin cells
(CCD-1064sk) by MTT assay. These results agree with a
previous work that suggested that venom toxins specifically
targets cancer cells without affecting normal ones [23]. It
indicates a difference of cell membranes between cancer
and normal cells, which reveals the variation of phospho-
lipid domains in different cell types [14, 18, 28, 29].
Apoptosis is a programmed cell death that occurs as a
defense mechanism when cells are irrecoverably dam-
aged. Either lost of apoptosis function or the imbalance
between cell division and cell death happen in case of
cancer. Therefore, the induction of apoptosis pathway is a
way to control the proliferation and inhibition of cancer
progression. The effect of dssPLA2 (0.25 and 0.5 μg/mL)
on apoptosis (17.6 % and 30.60 %) at 24 h of incubation
suggests that dssPLA2 induced moderate apoptosis on SK-
MEL-28 cells. Apoptosis pathway contains multiple cas-
cades that may be investigated by various techniques.
AnnexinV-FITC is a tool to detect phosphatidylserine (PS)
on the cell surface in initiating apoptosis. Optimization of
concentration and incubation period of dssPLA2 in order
to provoke apoptosis on SK-MEL-28 cells could be im-
proved in further studies. There were a couple of effects
of dssPLA2 on SK-MEL-28 cells at 24 h of incubation.
First, dssPLA2 induced apoptosis on SK-MEL-28 cells. In
that moment, it had also provoked 31.60, 41.66, 50.0 and
68.75 % of migration inhibition at the following concen-
trations: 0.25, 0.5, 1 and 2 μg/mL. dssPLA2 (0.25 and
0.5 μg/mL) had induced death on SK-MEL-28 cells (23.19
and 37.65 %) at 24 h. The remaining surviving cells (76.81
Fig. 2 Viability of SK-MEL-28 and CCD-1064sk cells treated with dssPLA2
for 24 and 72 h. Data are expressed as means ± SE of triplicates (n= 4).
Treatment that significantly differed from untreated control for 24 and
72 h at p< 0.05 are indicated as * and ** respectively. *** p< 0.05





























Fig. 3 Total apoptosis and necrosis of SK-MEL-28 cells were induced
by incubation with dssPLA2 for 24 h. Results are expressed as































Fig 4 Inhibition of SK-MEL-28 cell migration by dssPLA2 from
Daboia siamensis venom compared with doxorubicin (anticancer
drug) for 24 h. Results are expressed as mean ± SE (n = 4). Significant
differences between untreated and treated cells are presented as
*p < 0.001. ** p < 0.001 indicates significant differences between
dssPLA2 and doxorubicin at the same concentration
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and 62.35 %) resisted apoptosis and necrosis, and could
migrate. Therefore, the cells migration might be inhibited
due to other effects of dssPLA2. The minimum concentra-
tion of SK-MEL-28 cells (1 × 105 cells/mL) could close a
scratch within 24 h without inhibitors (Additional file 1).
The results indicated that dssPLA2 had different actions
in apoptosis and inhibition of migration on SK-MEL-28
cells at 24 h. However, both effects of dssPLA2 should be
studied further.
One of the treatments for metastatic melanoma is
based on BRAF V600E mutation gene. The BRAF
V600E mutation gene has been reported to promote
cancer cell survival and proliferation. This is found in
most malignant melanomas [6, 30, 31]. Many selective
small molecule inhibitors of BRAF V600E have been
studied. Similarly to vemurafenib and dabrafenib, BRAF
V600E mutation gene inhibitors have a limitation by fre-
quent and rapid onset of resistance [4, 8, 9, 32].
In our study, qRT-PCR was used to determine the
mRNA expression of BRAF V600E mutation on SK-
MEL-28 cells treated by dssPLA2, compared with un-
treated control. In melanoma cancer, the mutation of
BRAF V600 induced the hyperactive BRAF kinase activ-
ity and led to promote the uncontrolled cell proliferation
[32]. The BRAF V600E mutation gene was a targeting to
melanoma cancer treatment. Therefore, we examined
the effect of dssPLA2 on BRAF V600E mutation gene to
melanoma therapy. Moreover, Notch signaling genes,
which are the cell cycle regulation genes, were also in-
vestigated in the same experiment. The Notch signaling
pathway plays an important role in balance on the cell
proliferation, differentiation and apoptosis pathways.
Dysfunction in Notch pathway is connected with tumor
mutagenesis in various tissues [12, 13, 30]. When those
genes were blocked, the characteristic cell death would
appear and dssPLA2 might be useful in treatment of this
cancer.
The mRNA expression level of N1, N2, N3 and BRAF
V600E genes between treated and untreated SK-MEL-28
cells were not significantly changed after 24 h incubation
(Fig. 5). This result indicated that dssPLA2 had no effect
of N1, N2, N3 and BRAF V600E mutation genes and
were not related to induction of apoptosis and inhibition






















































































































Fig. 5 mRNA expression level of Notch1, Notch2, Notch3 and BRAF V600E mutation genes on SK-MEL-28 cells were induced by 0.25 μg/mL of
dssPLA2 for 24 and 72 h. The values represent relative gene expression compared to untreated cells. Significant differences between untreated
and treated cells are presented as *p < 0.001. ** p < 0.001 indicates difference between 24- and 72-h treatment at the same concentration
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in the mRNA expression level of N1 and BRAF V600E
mutation genes were observed on SK-MEL-28 cells after
72 h of incubation with dssPLA2 compared with un-
treated cells (Fig. 5a and d). This suggested that N1 and
BRAF V600E genes may be connected with induction of
cytotoxic process by dssPLA2 due to the mortality on
SK-MEL-28 cells. A number of studies have examined the
potential of Notch signaling genes by various agents. The
results of these studies showed that down regulation of
Notch signaling genes are similar to using dssPLA2. For
example, down regulation of Notch1 provoked inhibition
of cell growth and apoptosis in cancer cells [10, 11]. In
contrast, the increased expression of Notch components
was associated with a worse prognosis for cancer and a
shorter survival rate [13]. Synthetic substances and natural
products have been studied in order to find a melanoma
inhibitor concerning this gene. For example, xanthones
significant inhibited mRNA expression of BRAF V600E
mutation gene at 48 h [6]. Numerous inhibitors – such as
vemurafenib, dabrafebib and trametinib – are potential
substances of interest since they target BRAF V600E and
MAPK signaling. Unfortunately, the disease could re-
emerge and escape from therapy. Therefore, the effect of
dssPLA2 on melanoma should be evaluated in several as-
pects, especially resistance mechanisms focusing on BRAF
V600E mutation gene and BRAF protein. dssPLA2 is a po-
tential candidate against melanoma that would prevent
the recurrence of the disease.
Conclusions
We reported the effects of dssPLA2, a phospholipase A2
from Daboia siamensis venom, activity on SK-MEL-28
cells. This enzyme strongly inhibited migration and cyto-
toxicity and showed significant down regulation of N1 and
BRAF V600E mutation genes on SK-MEL-28 cells that
might lead to cell damage and death. Interestingly, it pre-
sented no toxicity towards CCD-1064sk, a normal skin cell.
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